JPWO2019241442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241442A5 JPWO2019241442A5 JP2020569024A JP2020569024A JPWO2019241442A5 JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5 JP 2020569024 A JP2020569024 A JP 2020569024A JP 2020569024 A JP2020569024 A JP 2020569024A JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- item
- dose
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 201000003895 major depressive disease Diseases 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 10
- 206010012378 Depression Diseases 0.000 claims description 9
- 230000003920 cognitive function Effects 0.000 claims description 8
- 201000009916 postpartum depression Diseases 0.000 claims description 7
- 206010054089 Depressive symptom Diseases 0.000 claims description 6
- 206010004939 Bipolar I disease Diseases 0.000 claims description 5
- 206010004938 Bipolar disease Diseases 0.000 claims description 5
- 206010057668 Cognitive disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 2
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023205211A JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684155P | 2018-06-12 | 2018-06-12 | |
US62/684,155 | 2018-06-12 | ||
US201962789329P | 2019-01-07 | 2019-01-07 | |
US62/789,329 | 2019-01-07 | ||
US201962841645P | 2019-05-01 | 2019-05-01 | |
US62/841,645 | 2019-05-01 | ||
PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023205211A Division JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021527092A JP2021527092A (ja) | 2021-10-11 |
JPWO2019241442A5 true JPWO2019241442A5 (US20070167479A1-20070719-C00034.png) | 2022-06-16 |
Family
ID=67211854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020569024A Pending JP2021527092A (ja) | 2018-06-12 | 2019-06-12 | 19−ノルc3,3−二置換c21−n−ピラゾリルステロイドおよびその使用方法 |
JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法 |
Country Status (13)
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2806877T3 (pl) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
IL302480A (en) | 2016-08-23 | 2023-06-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
AU2020395246A1 (en) * | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
CA3176854A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
JP2024510436A (ja) * | 2021-03-17 | 2024-03-07 | セージ セラピューティクス, インコーポレイテッド | 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド |
JP2024515830A (ja) * | 2021-04-29 | 2024-04-10 | セージ セラピューティクス, インコーポレイテッド | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
KR20240006026A (ko) * | 2021-04-29 | 2024-01-12 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
WO2023158668A1 (en) * | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201508550XA (en) * | 2013-04-17 | 2015-11-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
PL3206493T3 (pl) * | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
MA43815A (fr) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
IL302480A (en) * | 2016-08-23 | 2023-06-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
TW202342058A (zh) * | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
-
2019
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en unknown
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018507243A5 (US20070167479A1-20070719-C00034.png) | ||
JPWO2019241442A5 (US20070167479A1-20070719-C00034.png) | ||
JP2020534270A5 (US20070167479A1-20070719-C00034.png) | ||
JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および/または代謝疾患の処置のための、脳由来神経栄養因子(bdnf)の誘導された発現 | |
JP2022116304A (ja) | 血液がんの治療のためのPPARγアゴニスト | |
JP2016507500A5 (US20070167479A1-20070719-C00034.png) | ||
JP2020504129A (ja) | 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法 | |
JP2016505050A5 (US20070167479A1-20070719-C00034.png) | ||
RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
EP1383495A1 (en) | Duloxetine for treatment of hot flashes | |
JP2018526345A (ja) | アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法 | |
WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
JP2023011549A5 (US20070167479A1-20070719-C00034.png) | ||
JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
AU2022201030A1 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
RU2721409C1 (ru) | Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови | |
US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
Oettmeier et al. | The procaine-base-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
RU2020143245A (ru) | 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения | |
JPWO2020023324A5 (US20070167479A1-20070719-C00034.png) | ||
RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
US20170196987A1 (en) | Methods for treating multiple sclerosis | |
CN108014336B (zh) | 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物 | |
TW202304424A (zh) | 包含依維莫司和安森司群的組合 |